Antiviral compounds
Granted: August 6, 2024
Patent Number:
12054507
The present disclosure provides a compound of Formula I: which is useful in treating a variety of diseases, such as diseases caused by respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, HCV and/or HBV infections.
Bridged tricyclic carbamoylpyridone compounds and uses thereof
Granted: August 6, 2024
Patent Number:
12054496
The present disclosure relates generally to compounds, of Formula I Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
Diacylglycerol kinase modulating compounds
Granted: August 6, 2024
Patent Number:
12054490
The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
HIV vaccines and methods of using
Granted: August 6, 2024
Patent Number:
12053517
Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and kits comprising such fusion polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HIV-1. Further provided are methods for design of antiviral vaccines, including vaccines to elicit an immune response against HIV-1.
Quinoline derivatives
Granted: August 6, 2024
Patent Number:
12053462
The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
Granted: July 30, 2024
Patent Number:
12049461
This invention provides quinazoline derivatives represented by the structural formula: (I); wherein: R2 is hydrogen, NR?R?, C1-7alkyl, arylC1-7 alkyl or C3-10 cycloalkyl; R4 is amino, C1-7alkyl, C2-7 alkenyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, aryl, heterocyclic, arylalkyl, heterocyclic-substituted C1-7alkyl or C3-10 cycloalkyl-C1-7 alkyl; R5 is hydrogen or C1-7 alkyl, or R5 and R4 together with the nitrogen atom to which they are attached form a heterocyclic ring; Y is a single bond,…
Substituted eneoxindoles and uses thereof
Granted: July 16, 2024
Patent Number:
12037342
The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
Pentacyclic derivatives as Zika virus inhibitors
Granted: July 16, 2024
Patent Number:
12037340
Provided herein are compounds of Formula (I): the formula(I): wherein the various substituents are defined herein.
Phospholipid compounds and uses thereof
Granted: July 9, 2024
Patent Number:
12030904
Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
Granted: July 9, 2024
Patent Number:
12030906
The present invention relates to novel salts and crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate for use in treating viral infections. In some embodiments, the viral infection is caused by a virus selected from the group consisting of Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, and Paramyxoviridae.
Antiviral compounds
Granted: July 9, 2024
Patent Number:
12030903
The present disclosure describes 4?-fluoromethyl nucleosides for treating viral infections, including Dengue.
Bridged tricyclic carbamoylpyridone compounds and uses thereof
Granted: July 2, 2024
Patent Number:
12024528
The present disclosure relates generally to compounds, of Formula I: Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
Methods of preparing 1?-cyano nucleosides
Granted: June 18, 2024
Patent Number:
12012431
The present disclosure generally describes methods of preparing 1?-cyano nucleosides, such as a compound of Formula (I). For example, the compound of Formula (I) can be prepared from a compound of Formula (II-a) in a flow reactor.
Diacylglycerol kinase modulating compounds
Granted: June 4, 2024
Patent Number:
11999733
The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
Granted: June 4, 2024
Patent Number:
11999717
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
Therapeutic compounds
Granted: May 28, 2024
Patent Number:
11993583
The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
Blister pack
Granted: May 28, 2024
Patent Number:
D1028737
Antibodies that target HIV GP120 and methods of use
Granted: May 21, 2024
Patent Number:
11987617
Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.
Blister pack
Granted: May 21, 2024
Patent Number:
D1027663
LPA receptor antagonists and uses thereof
Granted: May 14, 2024
Patent Number:
11980609
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (TLD), or chronic kidney disease (CKD).
